Published November 17, 2020 | Version v0.0.7

rxn4chemistry/rxnfp: Initial Zenodo release

  • 1. IBM Research - Europe | University of Bern
  • 2. University of Bern
  • 3. IBM Research - Europe

Description

RXNFP - chemical reaction fingerprints.

Code to convert reaction SMILES into fingerprints, classify chemical reactions and generate reaction atlases.

This release is complementing the Mapping the Space of Chemical Reactions using Attention-Based Neural Networks publication by Philippe Schwaller, Daniel Probst, Alain C. Vaucher, Vishnu H Nair, David Kreutter, Teodoro Laino and Jean-Louis Reymond.

Mapping the Space of Chemical Reactions using Attention-Based Neural Networks

Organic reactions are usually assigned to classes containing reactions with similar reagents and mechanisms. Reaction classes facilitate the communication of complex concepts and efficient navigation through chemical reaction space. However, the classification process is a tedious task. It requires the identification of the corresponding reaction class template via annotation of the number of molecules in the reactions, the reaction center, and the distinction between reactants and reagents. This work shows that transformer-based models can infer reaction classes from non-annotated, simple text-based representations of chemical reactions. Our best model reaches a classification accuracy of 98.2%. We also show that the learned representations can be used as reaction fingerprints that capture fine-grained differences between reaction classes better than traditional reaction fingerprints. The insights into chemical reaction space enabled by our learned fingerprints are illustrated by an interactive reaction atlas providing visual clustering and similarity searching.

Files

rxn4chemistry/rxnfp-v0.0.7.zip

Files (349.9 MB)

Name Size
md5:a04be751b00471e8e4c29f4544605721
349.9 MB Preview Download

Additional details

Related works

Funding

Swiss National Science Foundation
NCCR TransCure: From transport physiology to identification of therapeutic targets (phase III) 51NF40-185544